Long QT Syndrome 3 Latest Advances

Journal: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Published: November 16, 2017

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.

Journal: Heart rhythm

Published: February 15, 2017

Fatal ventricular arrhythmias in a young male with unrecognized LQT3 and cardiolaminopathy.

Journal: Journal of cardiovascular medicine (Hagerstown, Md.)

Published: January 25, 2017

Sevoflurane prolonged the QTc interval and increased transmural dispersion of repolarization in a patient with long QT syndrome 3: a case report.

Journal: JA clinical reports

Published: September 05, 2016

Reply to the Editor--Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.

Journal: Heart rhythm

Published: December 11, 2013

Customize your search results with filters

Long QT Syndrome: LQT3 Variant Presenting in a Bradycardic Newborn.

Long QT Syndrome: LQT3 Variant Presenting in a Bradycardic Newborn.

Diagnostic lacunae and implications of an automated implantable cardioverter defibrillator implantation in a child with type 3 Long QT (LQT3) syndrome.

Diagnostic lacunae and implications of an automated implantable cardioverter defibrillator implantation in a child with type 3 Long QT (LQT3) syndrome.

Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review.

Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review.

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3.

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3.

Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.

Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.

Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3).

Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3).

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.

Fatal ventricular arrhythmias in a young male with unrecognized LQT3 and cardiolaminopathy.

Fatal ventricular arrhythmias in a young male with unrecognized LQT3 and cardiolaminopathy.

Sevoflurane prolonged the QTc interval and increased transmural dispersion of repolarization in a patient with long QT syndrome 3: a case report.

Sevoflurane prolonged the QTc interval and increased transmural dispersion of repolarization in a patient with long QT syndrome 3: a case report.

Reply to the Editor--Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.

Reply to the Editor--Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.